Overview

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Status:
Not yet recruiting
Trial end date:
2031-07-01
Target enrollment:
Participant gender:
Summary
compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Treatments:
Carboplatin
Cyclophosphamide
Docetaxel
Epirubicin
Pertuzumab
Trastuzumab